Living with obesity, diabetes, and other metabolic disorders often means lifelong treatment — impacting not only health, but daily life.
Despite important medical progress, many therapies come with trade-offs, including tolerability challenges, inconvenience, and inconsistent adherence.
Advancing treatment approaches that better align with patient needs remains essential.
Driving the future of diabetes treatment
Diabetology is driven by a team of experienced scientists, healthcare innovators, and biotechnology professionals dedicated to improving diabetes treatment. Founded by experts in pharmaceutical research, drug delivery technologies, and healthcare entrepreneurship, the company combines strong scientific knowledge with commercial expertise. Together, the team focuses on developing innovative oral therapies that aim to transform how diabetes is managed worldwide.
July 5, 2025
Press Release
Lifesciences Magazine: Battling Diabetes! Exclusive Interview with the Glen Travers (Co-founder of Diabetology Limited), Leading Biopharma Company Pushing Boundaries
Read More
NOvember 11, 2025
Publication
The objective of this paper is to demonstrate that oral insulin is potentially close to being commercialized, in light of the fact that (i) the technical, safety, and pharmacological obstacles in developing an oral insulin for clinical use for diabetes can potentially be overcome, and (ii) there are players in the field that are moving an oral insulin formulation into advanced clinical trials.
Read More
November 6, 2024
Publication
Results of preclinical studies with exenatide, semaglutide and other GLP-1 analogues in rodents and large animals. Description of mechanism of action of Diabetology' Axcess technology used in Capsulin.
Read More
Diabetology Limited
Diabetology (UK) Ltd
Diabetology (International) Ltd
Oral Capsule Technology for Insulin, GLP-1 and Other Protein-Based Therapies and Combinations.
Copyright © 2026 Diabetology Ltd. All rights reserved.
